• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.

作者信息

van der Velde Gabrielle, Pham Ba', Machado Márcio, Ieraci Luciano, Witteman William, Bombardier Claire, Krahn Murray

机构信息

Toronto Health Economics and Technology Assessment Collaborative and Institute for Work and Health, Toronto, Ontario, Canada.

出版信息

Arthritis Care Res (Hoboken). 2011 Jan;63(1):65-78. doi: 10.1002/acr.20338.

DOI:10.1002/acr.20338
PMID:20740606
Abstract
摘要

相似文献

1
Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.生物反应调节剂与改善病情抗风湿药治疗类风湿关节炎的成本效益：一项系统评价
Arthritis Care Res (Hoboken). 2011 Jan;63(1):65-78. doi: 10.1002/acr.20338.
2
Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA.目前类风湿关节炎生物制剂成本效益评估中的不足之处。
Nat Clin Pract Rheumatol. 2009 Feb;5(2):78-9. doi: 10.1038/ncprheum0985. Epub 2008 Dec 23.
3
Cost-effectiveness of biologics in early rheumatoid arthritis.生物制剂在早期类风湿性关节炎中的成本效益
Ann Intern Med. 2010 Mar 2;152(5):333-4; author reply 334. doi: 10.7326/0003-4819-152-5-201003020-00018.
4
Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.改善病情抗风湿药和生物制剂在类风湿关节炎中的疗效、耐受性及成本效益
Drugs. 2005;65(5):661-94. doi: 10.2165/00003495-200565050-00006.
5
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.采用对症治疗、改善病情抗风湿药或生物制剂治疗极早期类风湿关节炎：一项成本效益分析。
Ann Intern Med. 2009 Nov 3;151(9):612-21. doi: 10.7326/0003-4819-151-9-200911030-00006.
6
Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed?生物制剂作为类风湿关节炎一线治疗的成本效益：定论了吗？
Ann Intern Med. 2009 Nov 3;151(9):668-9. doi: 10.7326/0003-4819-151-9-200911030-00013.
7
The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.阿那白滞素治疗成人类风湿关节炎的临床疗效与成本效益：一项系统评价与经济分析
Health Technol Assess. 2004 May;8(18):iii-iv, ix-x, 1-105. doi: 10.3310/hta8180.
8
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.阿达木单抗、依那西普、英夫利昔单抗、聚乙二醇化赛妥珠单抗、戈利木单抗、托珠单抗和阿巴西普用于治疗既往未使用改善病情抗风湿药物治疗且仅在传统改善病情抗风湿药物治疗失败后的类风湿关节炎：系统评价和经济学评估。
Health Technol Assess. 2016 Apr;20(35):1-610. doi: 10.3310/hta20350.
9
The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.英格兰针对能够耐受甲氨蝶呤的类风湿关节炎患者的生物改善病情抗风湿药物治疗序列的成本效益
J Rheumatol. 2017 Jul;44(7):973-980. doi: 10.3899/jrheum.160941. Epub 2017 Feb 15.
10
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.阿达木单抗、依那西普和英夫利昔单抗治疗成人类风湿关节炎有效性的系统评价及其成本效益的经济学评估。
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420.

引用本文的文献

1
An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review.用于治疗视网膜疾病的生物类似药介绍：一篇叙述性综述
Ophthalmol Ther. 2022 Jun;11(3):959-982. doi: 10.1007/s40123-022-00488-w. Epub 2022 Mar 12.
2
EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis.欧洲抗风湿病联盟（EULAR）关于以工作参与作为炎症性关节炎患者结局领域的研究设计、分析和报告的要点考量
Ann Rheum Dis. 2021 Sep;80(9):1116-1123. doi: 10.1136/annrheumdis-2020-219523. Epub 2021 Apr 8.
3
Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World.
甲氨蝶呤（MTX）联合羟氯喹与MTX联合来氟米特治疗甲氨蝶呤抵抗的活动性类风湿关节炎患者：一项为期2年的真实世界队列研究
J Inflamm Res. 2020 Dec 18;13:1141-1150. doi: 10.2147/JIR.S282249. eCollection 2020.
4
Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis.甲氨蝶呤治疗失败的类风湿关节炎患者早期使用原研生物制剂或其生物类似药的成本效益。
Adv Ther. 2019 Aug;36(8):2086-2095. doi: 10.1007/s12325-019-00986-7. Epub 2019 May 30.
5
Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis.治疗类风湿关节炎生物制品的价格比较分析
Front Pharmacol. 2018 Sep 20;9:1070. doi: 10.3389/fphar.2018.01070. eCollection 2018.
6
Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable Analysis.生物制剂治疗类风湿关节炎是否能抵消治疗相关的资源利用和成本？文献综述和工具变量分析。
Curr Rheumatol Rep. 2017 Sep;19(9):54. doi: 10.1007/s11926-017-0680-6.
7
Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.在希腊，对中重度活动期类风湿关节炎患者，采用培塞利珠单抗联合甲氨蝶呤进行成本-效用分析。
Rheumatol Int. 2017 Sep;37(9):1441-1452. doi: 10.1007/s00296-017-3736-z. Epub 2017 May 18.
8
Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry.在确诊类风湿关节炎中采用达标治疗策略实现临床缓解的成本效益：CREATE注册研究结果
Rheumatol Int. 2016 Dec;36(12):1627-1632. doi: 10.1007/s00296-016-3583-3. Epub 2016 Oct 24.
9
Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data.尽管接受甲氨蝶呤治疗，但仍发生快速放射学进展的早期类风湿关节炎患者的识别用基质的表现：基于 ESPOIR 队列数据的外部验证研究。
RMD Open. 2016 May 20;2(1):e000245. doi: 10.1136/rmdopen-2016-000245. eCollection 2016.
10
Assessment of Rheumatoid Arthritis Quality Process Measures and Associated Costs.类风湿性关节炎质量过程指标及相关成本评估
Popul Health Manag. 2017 Feb;20(1):31-40. doi: 10.1089/pop.2015.0133. Epub 2016 Mar 31.